Endo International plc [NASDAQ: ENDP] loss -29.70% on the last trading session, reaching $1.42 price per share at the time. The company report on May 5, 2022 that ENDO REPORTS FIRST-QUARTER 2022 FINANCIAL RESULTS.
Endo International plc (NASDAQ: ENDP) today reported financial results for the first-quarter ended March 31, 2022 and provided second-quarter 2022 financial guidance.
“Despite challenging market dynamics for VASOSTRICT®, our first-quarter financial performance was in-line with our expectations with growth in our Branded Specialty Products portfolio driven by XIAFLEX® and our Generics segment driven by varenicline, the only FDA approved generic for Chantix®,” said Blaise Coleman, Endo’s President and Chief Executive Officer. “As we manage through the VASOSTRICT® loss of exclusivity over the near term, we remain focused on investing to advance our product portfolio for the long term. This includes executing on our XIAFLEX® maximization initiative, furthering our commitment to making QWO® the cornerstone treatment for cellulite through the expected launch of a new clinical study later this quarter, and bolstering our sterile injectables product pipeline with our recently announced acquisition.”.
Endo International plc represents 232.17 million in outstanding shares, while the company has a total market value of $474.90 million with the latest information. ENDP stock price has been found in the range of $1.28 to $1.5199.
If compared to the average trading volume of 4.70M shares, ENDP reached a trading volume of 20773352 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Endo International plc [ENDP]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ENDP shares is $2.70 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ENDP stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Piper Sandler have made an estimate for Endo International plc shares, keeping their opinion on the stock as Underweight, with their previous recommendation back on May 06, 2022. While these analysts kept the previous recommendation, Barclays dropped their target price from $5 to $2. The new note on the price target was released on March 02, 2022, representing the official price target for Endo International plc stock. Previously, the target price had yet another drop from $10 to $3, while Piper Sandler kept a Neutral rating on ENDP stock.
The Average True Range (ATR) for Endo International plc is set at 0.23, with the Price to Sales ratio for ENDP stock in the period of the last 12 months amounting to 0.16. Price to Free Cash Flow for ENDP in the course of the last twelve months was 1.67 with Quick ratio for the last quarter at 1.60.
Trading performance analysis for ENDP stock
Endo International plc [ENDP] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -29.00. With this latest performance, ENDP shares dropped by -38.26% in over the last four-week period, additionally sinking by -71.26% over the last 6 months – not to mention a drop of -74.78% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ENDP stock in for the last two-week period is set at 26.90, with the RSI for the last a single of trading hit 21.26, and the three-weeks RSI is set at 30.63 for Endo International plc [ENDP]. The present Moving Average for the last 50 days of trading for this stock 2.3546, while it was recorded at 2.0060 for the last single week of trading, and 3.5762 for the last 200 days.
Endo International plc [ENDP]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Endo International plc [ENDP] shares currently have an operating margin of +25.45 and a Gross Margin at +59.21. Endo International plc’s Net Margin is presently recorded at -19.01.
Endo International plc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.60 and a Current Ratio set at 1.80.
An analysis of insider ownership at Endo International plc [ENDP]
There are presently around $268 million, or 81.00% of ENDP stock, in the hands of institutional investors. The top three institutional holders of ENDP stocks are: BLACKROCK INC. with ownership of 36,827,860, which is approximately 1.1% of the company’s market cap and around 0.50% of the total institutional ownership; VANGUARD GROUP INC, holding 27,588,369 shares of the stock with an approximate value of $39.17 million in ENDP stocks shares; and PAULSON & CO. INC., currently with $24.6 million in ENDP stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Endo International plc stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 117 institutional holders increased their position in Endo International plc [NASDAQ:ENDP] by around 29,387,787 shares. Additionally, 87 investors decreased positions by around 16,356,860 shares, while 32 investors held positions by with 142,988,713 shares. The mentioned changes placed institutional holdings at 188,733,360 shares, according to the latest SEC report filing. ENDP stock had 50 new institutional investments in for a total of 11,840,214 shares, while 31 institutional investors sold positions of 2,062,573 shares during the same period.